National, retro- and prospective, observational, multicenter clinical research platform to connect clinical and genomic data of patients with advanced (locally advanced, inoperable, or metastatic) solid tumors (excluding NSCLC, SCLC, and mesothelioma) with results from multi-gene next-generation sequencing (NGS) panels (\>30 genes)
The AIO-BNHO CONNECT research platform is a clinic-genomic database collecting data on NGS results and corresponding clinical outcomes in patients with advanced solid tumors (excluding NSCLC, SCLC, and mesothelioma). Data of deceased patients will be included. The platform will provide insight into the current state of precision oncology in Germany by compiling real-world data encompassing a broad spectrum of care providers including but not limited to practice-based oncologists, community hospitals, and university hospitals. The platform also comprises a decentral tissue repository with clinically annotated tumor specimens retrieved within routine clinical care that can be used in future collaborative research projects.
Study Type
OBSERVATIONAL
Enrollment
3,000
Minimal data documentation only of patients without targeted therapy based on NGS results
Extended data documentation of patients with targeted therapy based on NGS results
Praxis für interdisziplinäre Onkologie & Hämatologie
Freiburg im Breisgau, Baden-Wurttemberg, Germany
RECRUITINGMedizinische Fakultät Mannheim der Universität Heidelberg
Mannheim, Baden-Wurttemberg, Germany
NOT_YET_RECRUITINGKlinikum der Universität München
München, Bavaria, Germany
NOT_YET_RECRUITINGMolecular tumorboard utilization
Proportion of patients who's case was discussed in a Molecular tumorboard
Time frame: 3 years
Treatment reality after NGS analysis
Proportion of patients who received at least one targeted therapy based on NGS results, who exclusively received therapies other than targeted therapies based on NGS results or who did not receive any therapy
Time frame: 3 years
NGS
Genomic alterations identified by multi-gene NGS panels
Time frame: 3 years
Molecular tumorboard
Descriptive analysis of MTB-based therapy recommendations, their implementation rate and reasons for non-implementation
Time frame: 3 years
Overall response rate
Overall response rate of targeted therapy based on NGS results
Time frame: 3 years
Progression-free survival (PFS)
Progression-free survival from start of targeted therapy based on NGS results
Time frame: 3 years
Overall survival
Overall survival from start of targeted therapy based on NGS results
Time frame: 3 years
PFS ratio
PFS interval associated with targeted therapy(ies) administered after NGS analysis divided by the time to progression (TTP) interval associated with the last prior treatment(s)
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.